Bellevue Asset Management (Switzerland)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$2.26M	Sell	24,000 -8,000	-25%	-$742K	0.34%	82
2015 Q3	$2.57M	Sell	32,000 -22,000	-41%	-$2.44M	0.42%	75
2015 Q2	$6.47M	Sell	54,000 -10,000	-16%	-$1.2M	0.9%	40
2015 Q1	$6.68M	Buy	+64,000	New	+$6.49M	0.93%	40

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ALNY Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) reduced its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q4 2015, selling an estimated $742K and leaving 24,000 shares worth $2.26M. The position accounts for 0.34% of the portfolio, ranked #82.

Bellevue Asset Management (Switzerland) first reported a position in ALNY in Q1 2015 and has held it in 4 quarters since. The position peaked at $6.68M in Q1 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

Bellevue Asset Management (Switzerland) held 24,000 shares of Alnylam Pharmaceuticals worth $2.26M as of Q4 2015.
Bellevue Asset Management (Switzerland) sold 8,000 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $742K.
Alnylam Pharmaceuticals made up 0.34% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #82 holding.
Bellevue Asset Management (Switzerland) first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
Bellevue Asset Management (Switzerland)'s Alnylam Pharmaceuticals position peaked at $6.68M in Q1 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.